Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting

Prior treatment

• Participation in any clinical trial within 30 days prior to enrolment
• Patients hospitalized due to an exacerbation of their asthma within the last 4 weeks prior to enrolment.
• Actual or previous use of biologics for asthma treatment in the past 12 months

Other illness

• Tuberculosis (active or anamnestic)
• Hypersensitivity to the active substances or to any of the excipients listed in the SmPC

Other

• Diagnosis of COPD.
• All exclusion criteria listed in Trimbow 172/5/9 μg pMDI SmPC
• Pregnancy and lactation.

• Physician-confirmed clinical diagnosis of asthma according to GINA guidelines and treated for at least 3 years before inclusion
• Patients ≥ 18 years of age in ambulatory care
• Patients who are eligible for the use of Trimbow 172/5/9 μg pMDI according to the SmPC
  • patients who experienced one or more asthma exacerbation in the previous year AND
  • patients not adequately controlled according to the physician's clinical assessment despite the use of b1) LABA and high dose ICS OR b2) LABA and high-dose ICS + LAMA multi-inhaler triple therapy. FEV1\<80% at baseline. (spirometry performed at the visit 1 independently of the study or up to 30 days before the enrolment or within 3 days after Visit 1 is acceptable).
  • 5\. Inhaled asthma therapy was changed to Trimbow 172/5/9 μg pMDI no more than 2 weeks prior to OR on the day of study inclusion 6. Patient provided written, informed consent to study participation